| Business Summary | | Antares
Pharma,
Inc.
develops,
commercializes
and
markets
novel
delivery
solutions,
including
needle-free
and
mini-needle
injector
systems,
gel
technologies
and
transdermal
products.
The
Company
currently
distributes
its
needle-free
injector
systems
for
the
delivery
of
insulin
and
growth
hormone
in
over
20
countries
and
an
estradiol
transdermal
patch
for
hormone
replacement
therapy.
In
addition,
Antares
has
five
products
under
development
and
is
conducting
ongoing
research
to
create
new
technologies
that
combine
various
elements
of
the
Company's
portfolio.
Formed
in
2001
by
the
combination
of
Permatec
and
Medi-Ject
Corporation,
Antares
Pharma
has
corporate
and
research
facilities
located
in
Minneapolis,
Minnesota,
and
Basel,
Switzerland. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ANTR
develops,
commercializes
and
markets
novel
delivery
solutons
which
improve
both
the
efficiency
of
drug
therapies
and
the
quality
of
life
for
patients.
For
the
six
months
ended
6/30/01,
revenues
totaled
$1.7
million,
up
from
$256
thousand.
Net
loss
before
accounting
change
and
applicable
to
Common
totaled
$9.7
million,
up
from
$2.3
million.
Revenues
reflect
the
sale
of
Antares/Minnesota
injection
devices.
Net
loss
reflects
a
$5.4
million
charge
related
to
preferred
stock
dividend. | More
from
Market Guide: Significant
Developments |
| | |
| Position | Jacques Gonella | Chairman | Roger Harrison | CEO,
Director | Franklin Pass, M.D. | Vice
Chairman | Lawrence Christian | Sec. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|